Clinical trials: Terminal Cancer, open to volunteers
End-Stage Renal Disease, End Stage Renal Disease on Dialysis
CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk
This clinical trial investigates the transplantation of donor kidneys that have been genetically modified ex vivo using CRISPR-Cas9 genome editing to reduce immunogenicity and transplant rejection.
- Conditions
- End-Stage Renal Disease, End Stage Renal Disease on Dialysis, End Stage Renal Disease With Renal Transplant, Kidney Transplant Rejection
- Trial name
- NCT07053462
- Testing
- Ex Vivo CRISPR-Cas9 Gene Editing of Donor Kidney, Kidney Transplantation with Standard Care
- Where
- China
- Volunteers
- 90 people
- Sponsor
- AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Cannabidiol for Pain Relief of Patients With End-stage mCRPC
The goal of this clinical trial is to evaluate the effects of cannabidiol in patients with end-stage metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- ProCan (NCT07549256)
- Testing
- Cannabidiol
- Where
- Denmark
- Volunteers
- 58 people
- Sponsor
- Regionshospital Nordjylland
Liver Diseases, Liver Cancer
CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection
This early-phase clinical trial will assess the use of ex vivo CRISPR-Cas9 genome editing on donor liver grafts to reduce immunogenicity before transplantation.
- Conditions
- Liver Diseases, Liver Cancer, Liver Cirrhosis, Liver Failure
- Trial name
- NCT07053488
- Testing
- Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver
- Where
- China
- Volunteers
- 90 people
- Sponsor
- AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC
Advanced Cancer, Terminal Malignant Tumors
Nurses' Competence and Role in Survival Prediction and Prognostic Communication
[Background] Nurses' roles in survival prediction and prognostic communication have historically been limited due to role delineation, lack of formal training, and cultural norms.
- Conditions
- Advanced Cancer, Terminal Malignant Tumors, Hospices
- Trial name
- NCT06962553
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital